| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/25/2002 | WO2002056875A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056873A2 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues |
| 07/25/2002 | WO2002056872A2 Antiproliferative colchicine compositions and uses thereof |
| 07/25/2002 | WO2002056870A2 Method for treating sleep disorders |
| 07/25/2002 | WO2002056869A2 Method for treating sexual disorders |
| 07/25/2002 | WO2002056868A2 Method for treating stress or tension |
| 07/25/2002 | WO2002056867A2 Extended release pharmaceutical compositions containing beta-lactam antibiotics |
| 07/25/2002 | WO2002056866A1 A method for the preparation of nanoparticles |
| 07/25/2002 | WO2002056864A2 Differential delivery of nitric oxide |
| 07/25/2002 | WO2002056852A1 Cosmetics |
| 07/25/2002 | WO2002056849A1 Hair growth stimulants |
| 07/25/2002 | WO2002056835A2 Anticancer treatment using triptolide prodrugs |
| 07/25/2002 | WO2002056834A2 Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts |
| 07/25/2002 | WO2002056832A2 Methods to treat autoimmune and inflammatory conditions |
| 07/25/2002 | WO2002056827A2 Substituted felbamate derived compounds |
| 07/25/2002 | WO2002056826A2 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 07/25/2002 | WO2002056825A2 Composition and method to increase calcium levels in animals |
| 07/25/2002 | WO2002056823A2 Redox therapy for tumors |
| 07/25/2002 | WO2002056808A1 Bioadhesive cell foam film of sustained-release delivery |
| 07/25/2002 | WO2002056804A2 Presbyopia treatment by lens alteration |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056755A2 Method for treating cancer |
| 07/25/2002 | WO2002056753A2 P27 prevents cellular migration |
| 07/25/2002 | WO2002056745A2 Method of treating parkinson's disease |
| 07/25/2002 | WO2002056708A2 Preparation for improved dietary utilisation |
| 07/25/2002 | WO2002056699A1 Coated chewing gum products containing an acid blocker |
| 07/25/2002 | WO2002056692A1 Methods for modulating tumor growth and metastasis |
| 07/25/2002 | WO2002050061A8 Piperazine derivatives for treatment of bacterial infections |
| 07/25/2002 | WO2002044161A3 A process for the preparation of taxan derivatives |
| 07/25/2002 | WO2002043663A3 Tetrapartate prodrugs |
| 07/25/2002 | WO2002043652A3 Anti-proliferative drugs |
| 07/25/2002 | WO2002042268A3 Ep4 receptor selective agonists in the treatment of osteoporosis |
| 07/25/2002 | WO2002040041A3 Orally ingestible preparation of mistletoe lectins and method |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002039960A3 Cosmetic method of treating skin |
| 07/25/2002 | WO2002039879A3 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 07/25/2002 | WO2002038077A3 L-histidine in ophthalmic solutions |
| 07/25/2002 | WO2002036591A3 Inhalative solution formulation containing a tiotropium salt |
| 07/25/2002 | WO2002036071A3 Method of treating and preventing migraine headaches |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032874A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002030867A3 Drugs for diabetes |
| 07/25/2002 | WO2002020466B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002017918A3 Sustained release formulations for growth hormone secretagogues |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002015884A3 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002015851A3 Storage stable tretinoin and 4-hydroxy anisole containing topical composition |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002013764A3 Methods for treating subjects infected with a herpes virus or neisseria gonorrheae |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002008177A3 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 07/25/2002 | WO2002005849A3 Transportation of nucleic acid substances |
| 07/25/2002 | WO2002002147A3 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 07/25/2002 | WO2002000653A3 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 07/25/2002 | WO2002000183A3 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 07/25/2002 | WO2001097872B1 Bioadhesive compositions and methods of preparation and use |
| 07/25/2002 | WO2001095896A3 Protein phosphatase 2a inhibitors to inhibit host-cell mediated viral replication |
| 07/25/2002 | WO2001093877A3 Epithelial cell cancer drug |
| 07/25/2002 | WO2001093865A3 Medicaments for treating dementia |
| 07/25/2002 | WO2001092891A3 Regulating lipid levels via the zmax1 or hbm gene |
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001089510A3 Use of an ampa receptor potentiator for the treatment of obesity |
| 07/25/2002 | WO2001088126A3 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 07/25/2002 | WO2001087307A3 Compositions and methods for the treatment of cancer |
| 07/25/2002 | WO2001082919B1 Methods of and compounds for inhibiting calpains |
| 07/25/2002 | WO2001080894A3 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| 07/25/2002 | WO2001078781A9 Methods for prevention and treatment of gastrointestinal disorders |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | WO2001074346A3 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001070222A3 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 07/25/2002 | WO2001068096A3 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| 07/25/2002 | WO2001068079A3 Viscoelastics for use in middle ear surgery |
| 07/25/2002 | WO2001068073A8 Method for improving respiratory function and inhibiting muscular degeneration |
| 07/25/2002 | WO2001066721A3 Nucleic acid sensor molecules |
| 07/25/2002 | WO2001066531A8 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 07/25/2002 | WO2001064193A3 Exemestane for first-line treatment of breast cancer |
| 07/25/2002 | WO2001062289B1 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 07/25/2002 | WO2001047516A9 Immunosuppressants |
| 07/25/2002 | WO2001040188A9 Curcumin analogues for treating cancer |
| 07/25/2002 | WO2001036048A9 Phorboxazole derivatives for treating cancer |
| 07/25/2002 | WO2001034201A9 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 07/25/2002 | WO2001034094A9 Novel compounds to treat diabetes and associated conditions |
| 07/25/2002 | WO2001032186A3 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 07/25/2002 | WO2001015676A3 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 07/25/2002 | WO2001007056A9 Method of promoting bone growth with hyaluronic acid and growth factors |
| 07/25/2002 | WO2001003716A9 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 07/25/2002 | WO2001002559A9 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 07/25/2002 | WO2001000665A9 Inhibitors of memapsin 2 and use thereof |
| 07/25/2002 | WO2000059486A8 Use of cyp2d6 inhibitors in combination therapies |
| 07/25/2002 | US20020100069 Treating heart defects; obtain tissue, incubate with modulator of transcription, evaluate tissue for defect |
| 07/25/2002 | US20020099377 Mating insertion instruments for spinal implants and methods of use |
| 07/25/2002 | US20020099330 No-releasing compounds are a stabilized s-nitrosyl group and free thiol group coated on medical device, such as a stent or catheter |
| 07/25/2002 | US20020099222 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 07/25/2002 | US20020099220 Calcilytic compounds |
| 07/25/2002 | US20020099217 Process for preparing azacycloalkanoylaminothiazoles |
| 07/25/2002 | US20020099216 Compounds useful in therapy |